ストックスクリーナーアプリを入手
2.14
3.38%
0.07
プレマーケット:
2.14
C 4 Therapeutics Inc (CCCC) 最新ニュース
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New C4 Therapeutics hire granted options on 85,480 shares - Stock Titan
Volume Report: Is FAMI a good ESG investmentQuarterly Profit Review & Smart Money Movement Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
FY2028 EPS Forecast for C4 Therapeutics Reduced by Analyst - MarketBeat
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock By Investing.com - Investing.com Australia
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock - Investing.com
Insider Sell: Leonard Reyno Sells Shares of C4 Therapeutics Inc (CCCC) - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Leonard Reyno Sells 10,000 Shares of C4 Therapeutics (NASDAQ:CCCC) Stock - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Aug Intraday: Is Coincheck Group NV stock good for income investorsJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors - TipRanks
C4 Therapeutics to advance cemsidomide trials for multiple myeloma By Investing.com - Investing.com Nigeria
C4 Therapeutics (CCCC) Announces Ambitious Milestones Through 20 - GuruFocus
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - Investing News Network
C4 Therapeutics to advance cemsidomide trials for multiple myeloma - Investing.com
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide - TradingView
C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028 - Quiver Quantitative
Potential multiple myeloma drug from C4 Therapeutics plans trials to 2028 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch - TipRanks
How C4 Therapeutics Inc. stock performs in weak economy - Улправда
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock trading at a premium valuationWeekly Trend Recap & Smart Swing Trading Techniques - Улправда
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Is C4 Therapeutics Inc. stock in correction or buying zoneJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Is C4 Therapeutics Inc. stock oversold or undervaluedMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
How C4 Therapeutics Inc. stock benefits from tech adoptionQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Market Rankings: Is C4 Therapeutics Inc stock oversold or undervaluedQuarterly Portfolio Review & Breakout Confirmation Alerts - moha.gov.vn
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):